A novel LACC1 variant c.658G>A (p. Asp220Asn) in familial juvenile arthritis: identification and functional analysis. [PDF]
Alblooshi H +10 more
europepmc +1 more source
Approach to Nail Pitting in Pediatric and Adolescent Patients: A Dermatology Perspective
ABSTRACT This narrative review aims to discuss the etiologies of nail pitting in pediatric and adolescent patients, while providing a framework for further evaluation of possible underlying systemic conditions and their clinical findings from a dermatologic standpoint.
Elizabeth Botto +3 more
wiley +1 more source
Assessing the Association of Serum Zinc and Copper Levels With Disease Activity Using the Juvenile Arthritis Disease Activity Score (JADAS) in Juvenile Idiopathic Arthritis. [PDF]
Sultana T +4 more
europepmc +1 more source
ABSTRACT Introduction/Aims Comorbidities are frequent in myasthenia gravis (MG) and may affect treatment choices. Conversely, MG treatments may impact the risk of comorbidity. Our objective was to examine comorbidity and MG treatment patterns in nationwide MG cohorts in Denmark, Finland, and Sweden. Methods We included individuals with ≥ 2 MG diagnoses
Sari Atula +11 more
wiley +1 more source
Ethnic heterogeneity of juvenile arthritis in the Republic of Sakha (Yakutia) related to a high human leukocyte antigen B27 frequency. [PDF]
Boeskorova S +6 more
europepmc +1 more source
Diacylglycerol Kinase ζ Regulates Macrophage Responses in Juvenile Arthritis and Cytokine Storm Syndrome Mouse Models. [PDF]
Mahajan S, Mellins ED, Faccio R.
europepmc +1 more source
ABSTRACT Background In the InPedILD trial, nintedanib had an acceptable safety profile in children and adolescents (aged 6−17 years) with fibrosing ILDs. The open‐label extension of the InPedILD trial, InPedILD‐ON, is assessing the longer‐term safety of nintedanib in these patients. Methods Patients who completed the InPedILD trial on treatment and had
Robin Deterding +14 more
wiley +1 more source
Correction: Benefits of a Juvenile Arthritis Support Program (JASP-1) for children recently diagnosed with Juvenile Idiopathic Arthritis and their parents. [PDF]
Mördrup K +4 more
europepmc +1 more source
ABSTRACT While the efficacy of canakinumab, an anti‐interleukin‐1β monoclonal antibody, is well‐established, its safety profile, particularly across different age groups, remains inadequately explored. Using the FDA Adverse Event Reporting System (FAERS) database, this study evaluated postmarketing safety by analyzing adverse event (AE) reports from ...
Youyang Wang +3 more
wiley +1 more source
Assessing disparities through missing race and ethnicity data: results from a juvenile arthritis registry. [PDF]
Banschbach KM +14 more
europepmc +1 more source

